skip to main content


Crediting Preemption: Credit Suisse IPO case strengthens the FDA's argument for the preemption of state law failure-to-warn claims

Drug and Device Law

July 30, 2007

Authors: Adam M. Masin

Suggesting that the Supreme Court should view federal preemption issues in the pharmaceutical context based on analogous rationale outside that context.  

Click here for the full article.


© Shipman & Goodwin LLP, 2018. All Rights Reserved.